Bites and Stings

Spotted black snake (Pseudechis guttatus) envenoming

Melanie Jansen, Monique McLeod, Julian White and Geoffrey K Isbister

We report two cases of spotted black snake (Pseudechis guttatus) envenoming. One patient experienced localised burning pain around the bite and developed nausea, vomiting, diarrhoea, upper abdominal cramping and diaphoresis. He was treated with intravenous fluids and antiemetics, but no antivenom, and was discharged 23 hours after the bite. The second patient developed a severe headache, blurred vision and mild nausea, associated with severe pain and swelling of the bitten limb that took 4 days to resolve.

No antivenom was given and the patient had no sequelae. Neither patient developed significant coagulopathy, myolysis or neuromuscular paralysis. Bites by this species appear to cause effects similar to those of the more common red-bellied black snake (P. porphyriacus). (MJA 2007; 186: 41-42)

Clinical record

Patient 1

A 47-year-old male farmer in the Upper Hunter region of New South Wales was bitten by a spotted black snake and developed non-specific systemic effects with localised pain and swelling. The snake came from under a bale of hay and bit him on the dorsal aspect of the right foot. He applied a 7.5 cm elastic bandage up to the knee within 5 minutes, and arrived at the local hospital asymptomatic. The patient had no significant past medical history and took no regular medications. The dead snake was identified as Pseudechis guttatus by GKI, using a key for identification.1

The patient was transferred to a larger hospital 2 hours and 20 minutes post-bite, and the first aid was reinforced. He had no abnormalities on examination. Thirty minutes after arrival, he developed burning pain around the bite, associated with nausea, vomiting, diarrhoea, upper abdominal cramping, and diaphoresis. This was treated with 10 mg intravenous metoclopramide and intravenous fluids. A snake venom detection kit swab from the bite site was positive in the black snake well. He had persistent vomiting, which was treated with 8 mg ondansetron.

He was transferred to a tertiary hospital intensive care unit 7 hours post-bite. The symptoms gradually resolved, except for the activated partial thromboplastin time, which was marginally elevated (41 seconds; reference range, 25–40 seconds). The following day, 13 hours post-bite, he had a persistent headache, mild nausea and severe pain in the bitten hand. Although the systemic symptoms resolved over 12 hours, the bitten hand remained painful and swollen, requiring parenteral opiate analgesia. Forty-eight hours post-bite, the pain and swelling extended to the left elbow (Box 1B, C), with axillary adenopathy. He was treated with intravenous flucloxacillin and seen by the surgical team. Compartment pressures were within the normal range and no surgical intervention occurred. Four days post-bite, the pain and swelling were subsiding significantly (Box 1D). He was discharged on oral flucloxacillin and recovered over several days.

Discussion

Black snakes are found throughout Australia, with mulga snakes (Pseudechis australis) occurring across most of the mainland except...
the east coast. In the east, the most common is the red-bellied black snake \((P. porphyriacus)\), and most of the human population in this area will have encountered this snake at some stage. The spotted black snake or blue-bellied black snake \((P. guttatus)\) is less common, and primarily inhabits south-east Queensland and inland northern NSW. These cases suggest that spotted black snake bites are similar in effects to red-bellied black snake bites, including generalised systemic features and local effects, such as marked swelling and pain at the bite site. They were not similar to the more severe effects of mulga snakes and Collett's snake \((P. colletti)\), characterised by myotoxicity, anticoagulant coagulopathy and secondary renal impairment. The limited number of cases does not exclude the possibility that spotted black snake bite does occasionally cause significant myolysis like that from red-bellied black snake bite. Serum creatine kinase measurements should be done in all cases of spotted black snake bite with systemic envenoming.

There is only one previous report of a bite by a juvenile spotted black snake. In that case, localised necrosis at the bite site was treated with surgical debridement. However, the report only included photographs and little further information. Animal studies have demonstrated that spotted black snake venom is both neurotoxic and myotoxic, and both effects are neutralised by black and tiger snake antivenoms. However, neither of our patients had any evidence of significant neurotoxicity or myotoxicity that may be expected from in-vitro studies.

Neither patient was given antivenom, because there was no evidence of major systemic envenoming. As with red-bellied black snake envenoming, antivenom is only used when non-specific systemic effects do not respond to symptomatic treatment. It could be argued that, for Patient 1, who had ongoing vomiting, antivenom might have significantly reduced symptoms and resolved the vomiting, as it can do with red-bellied black snake bites. However, the vomiting responded to ondansetron, and use of antivenom always carries a risk of an allergic reaction. Although antibiotics were used in the second patient, the extensive local pain and swelling are more likely to be due to local venom effects and tissue reaction, also seen with red-bellied black snakes.

Acknowledgements

Geoff Isbister is supported by a National Health and Medical Research Council (NHMRC) Clinical Career Development Award ID300785.

Competing interests

Julian White is employed by the Women’s and Children’s Hospital, Adelaide, which is paid by CSL Ltd to provide a consultant clinical toxinology service for users of CSL antivenom and venom detection products.

Author details

Melanie Jansen, Medical Student
Monique McLeod, Medical Student
Julian White, MB BS, MD, Associate Professor, Consultant Clinical Toxinologist, Head of Toxinology
Geoffrey K Isbister, BSc, FACEM, MD, Senior Research Fellow, Clinical Toxicologist, Consultant Toxinologist
1 School of Medical Practice and Population Health, University of Newcastle, Newcastle, NSW.
2 Faculty of Health Sciences, University of Adelaide, Adelaide, SA.
3 Women’s and Children’s Hospital, Adelaide, SA.
4 Tropical Toxinology Unit, Menzies School of Health Research, Charles Darwin University, Darwin, NT.
5 NSW Poison Information Centre, The Children’s Hospital at Westmead, Sydney, NSW.
6 Department of Clinical Toxicology, Newcastle Mater Hospital, Newcastle, NSW.

Correspondence: gspitneferntee.com

References


(Received 26 Jul 2006, accepted 9 Oct 2006)